system
corticosteroid
treatment
found
effect
acut
treatment
secondari
prevent
asthma
young
wheez
children
limit
prior
studi
lack
subgroup
analys
might
identifi
respons
wheez
strongli
associ
recurr
wheez
asthma
age
previous
shown
two
random
control
trial
rct
wheez
children
use
post
hoc
prospect
design
cours
oral
corticosteroid
oc
may
reduc
risk
recurr
wheez
especi
children
high
rhinoviru
genom
load
previous
use
design
rct
effect
oc
treatment
wheez
recurr
wheez
children
investig
current
analysi
aim
investig
need
initi
regular
asthma
control
medic
base
previou
hypothes
children
high
rhinoviru
genom
load
effect
oc
like
last
beyond
month
reduc
need
initi
asthma
control
medic
studi
entri
patient
examin
studi
physician
blood
sampl
nasopharyng
aspir
taken
children
studi
physician
week
month
month
year
first
wheez
episod
parent
interview
studi
physician
use
standard
questionnair
studi
entri
electron
patient
chart
review
regard
asthma
medic
therapi
adher
asthma
symptom
full
period
random
protocol
describ
trial
clinicaltrialsgov
primari
outcom
time
initi
asthma
control
medic
age
year
initi
medic
base
nation
asthma
educ
prevent
program
naepp
guidelin
diagnosi
asthma
children
age
need
asthma
control
medic
defin
wheez
episod
diagnos
physician
within
year
last
day
affect
sleep
addit
one
major
risk
factor
physician
diagnos
atop
eczema
aeroallergen
sensit
parent
histori
asthma
two
minor
risk
factor
wheez
apart
cold
blood
eosinophil
count
food
sensit
andor
prolong
symptom
last
week
requir
symptomat
treatment
day
per
week
andor
two
exacerb
requir
system
corticosteroid
within
children
asthma
control
medic
start
third
acut
wheez
episod
accord
finnish
interact
analysi
includ
effect
rhinoviru
genom
load
ie
copi
number
effect
prednisolon
vs
placebo
main
outcom
pcr
test
use
detect
rhinoviru
speci
b
c
enterovirus
respiratori
syncyti
viru
rsv
b
nasopharyng
addit
multiplex
pcr
seeplex
ace
detect
seegen
seoul
korea
use
detect
rhinoviru
rsv
b
adenoviru
coronaviru
human
bocaviru
human
metapneumoviru
influenza
b
parainfluenza
viru
depart
virolog
univers
commerci
pcr
test
use
accord
experi
sensit
test
especi
concern
detect
rhinoviru
differ
rhinoviru
rsv
detect
either
multiplex
pcr
defin
posit
human
bocaviru
analyz
use
pcr
total
serum
immunoglobulin
e
ige
level
analyz
use
routin
diagnost
procedur
central
laboratori
turku
univers
hospit
sensit
defin
ige
antibodi
food
aeroallergen
phadiatop
phadia
uppsala
sweden
cutoff
level
kul
studi
central
laboratori
turku
univers
serum
oh
measur
made
mean
liquid
mass
spectrometri
massachusett
gener
hospit
boston
usa
laboratori
method
earlier
describ
origin
power
analysi
perform
baselin
differ
patient
characterist
treatment
group
analyz
use
test
age
u
test
total
ige
oh
rhinoviru
genom
load
durat
breast
feed
delay
start
studi
drug
test
sex
sensit
eczema
parent
allerg
rhiniti
patern
smoke
pet
ownership
coinfect
fisher
exact
test
count
admiss
ward
atop
eczema
parent
asthma
matern
smoke
viru
etiolog
cox
model
use
risk
primari
outcom
includ
main
effect
dichotom
rhinoviru
genom
load
intervent
group
interact
effect
rhinoviru
genom
load
intervent
group
cox
model
includ
covari
signific
differ
patient
characterist
found
surviv
time
censor
age
year
event
occur
earlier
cutoff
level
rhinoviru
genom
load
identifi
test
differ
copi
number
level
threshold
select
consid
signific
rhinoviru
load
vs
group
interact
effect
similar
previou
ibm
spss
version
spss
inc
chicago
ill
usa
use
statist
total
children
random
receiv
prednisolon
placebo
first
acut
wheez
episod
period
children
exclud
analysi
due
insuffici
time
dropout
nine
due
insuffici
data
rhinoviru
genom
load
one
due
initi
ic
anoth
reason
figur
final
children
analyz
inpati
outpati
exclud
patient
differ
includ
patient
accord
age
sex
atop
characterist
viral
etiolog
factor
list
tabl
tabl
studi
entri
mean
age
patient
month
standard
deviat
sd
month
sensit
eczema
tabl
twenti
children
least
two
virus
detect
airway
rhinoviru
genom
load
vari
across
patient
median
copiesml
interquartil
rang
iqr
patient
rhinoviru
genom
load
level
copiesml
tabl
median
delay
start
studi
drug
hour
iqr
treatment
group
differ
patient
characterist
shown
tabl
tabl
prednisolon
group
children
placebo
group
children
receiv
least
one
oc
cours
differ
cutoff
level
rhinoviru
genom
load
test
three
differ
level
notic
statist
signific
tabl
differ
final
result
differ
significantli
depend
cutoff
data
shown
level
earlier
report
asthma
control
medic
initi
children
prednisolon
group
placebo
group
children
diagnosi
base
wheez
episod
addit
risk
factor
seven
children
prolong
symptom
requir
symptomat
treatment
children
exacerb
requir
system
five
children
asthma
control
medic
start
third
acut
wheez
overal
prednisolon
affect
time
initi
asthma
control
medic
compar
placebo
figur
howev
level
rhinoviru
genom
load
studi
entri
modifi
effect
prednisolon
term
time
initi
asthma
control
medic
rhinoviru
load
x
studi
drug
interact
figur
children
rhinoviru
genom
load
copiesml
risk
initi
asthma
control
medic
lower
prednisolon
group
compar
placebo
group
hazard
ratio
hr
confid
interv
ci
figur
asthma
control
medic
exclus
start
children
high
rhinoviru
load
within
subsequ
month
first
wheez
episod
figur
median
age
children
time
initi
asthma
medic
month
iqr
month
children
rhinoviru
genom
load
copiesml
differ
found
prednisolon
placebo
group
hr
ci
figur
clinic
signific
advers
event
report
acut
phase
first
random
trial
investig
effect
oc
treatment
preschool
age
care
character
young
children
suffer
first
acut
wheez
episod
three
main
find
first
oc
found
effect
overal
regard
time
initi
asthma
control
medic
second
placebo
group
asthma
risk
high
regular
asthma
control
medic
initi
children
high
rhinoviru
genom
load
subsequ
month
first
acut
wheez
episod
third
short
cours
prednisolon
decreas
risk
asthma
control
medic
children
first
sever
wheez
episod
caus
high
rhinoviru
genom
load
find
line
previou
data
increas
asthma
risk
associ
earli
probabl
explan
associ
rhinoviru
infect
risk
asthma
may
airway
inflamm
children
predispos
rhinoviru
moreov
high
rhinoviru
genom
load
associ
sever
airway
patient
interferon
respons
defici
thu
increas
viru
replic
promot
type
respons
respiratori
epitheli
moreov
rhinoviru
infect
may
intensifi
inflamm
increas
express
eotaxin
interleukin
well
stimul
immigr
eosinophil
macrophag
placebo
group
find
except
high
risk
initi
regular
asthma
control
medic
children
high
rhinoviru
genom
load
consist
earlier
find
nevertheless
surpris
speed
asthma
progress
children
clinic
oc
treatment
recommend
asthma
exacerb
children
effect
oc
secondari
prevent
asthma
confirm
overal
analysi
rct
concern
children
suffer
earli
wheez
earlier
post
hoc
analysi
vinku
studi
children
first
wheez
episod
andor
eczema
benefit
prednisolon
treatment
term
lower
risk
recurr
wheez
unfortun
quantit
pcr
use
earlier
studi
contrast
rct
quantifi
viru
genom
load
earlier
analysi
report
prednisolon
treatment
reduc
recurr
wheez
group
children
rhinoviru
genom
load
copiesml
current
result
line
previou
find
support
view
risk
asthma
reduc
children
identifi
earli
treat
oc
oc
like
downregul
inflammatori
pathway
decreas
transcript
mani
inflammatori
gene
andor
transcript
factor
increas
express
variou
furthermor
start
acut
care
earli
may
import
rhinoviru
load
peak
earli
import
concentr
find
phenotyp
young
wheez
children
could
like
benefit
earli
oc
treatment
duma
et
use
cluster
approach
identifi
sever
phenotyp
sever
bronchiol
specul
rhinoviru
etiolog
andor
earli
atop
characterist
cluster
would
like
benefit
earli
intervent
trial
medic
prevent
recurr
wheez
asthma
studi
popul
especi
high
rhinoviru
load
like
repres
cluster
previou
studi
shown
higher
rhinoviru
genom
load
associ
sever
andor
longer
durat
acut
lower
respiratori
ill
previou
data
concern
outcom
beyond
use
sensit
pcr
pcr
compar
previou
studi
convent
pcr
liquid
hybrid
also
allow
quantif
rhinoviru
genom
load
also
use
highli
concentr
sampl
previou
studi
find
relationship
viral
shed
use
nasal
wash
sampl
estim
genom
load
differ
methodolog
may
explain
appar
discrep
result
earlier
studi
strength
studi
includ
care
character
patient
rct
design
although
blind
open
plan
howev
studi
limit
sampl
size
small
larg
enough
gener
statist
signific
result
consist
previou
patient
hospit
rais
question
generaliz
result
outpati
mild
wheez
rhinoviru
diagnost
caus
delay
administr
studi
drug
could
contribut
lack
effect
prednisolon
overal
rhinoviru
analysi
addit
sensit
pcr
earlier
post
hoc
analysi
delay
initi
studi
drug
quantit
rhinoviru
detect
prednisolon
found
effect
children
rhinoviru
andor
inflammatori
profil
helper
helper
mediat
differ
subgroup
would
increas
interest
find
profil
moreov
mani
cutoff
level
rhinoviru
genom
load
signific
studi
made
decis
line
earlier
summari
earli
system
prednisolon
treatment
may
benefici
reduc
risk
asthma
control
medic
first
year
wheez
preschool
children
whose
episod
sever
associ
high
rhinoviru
genom
load
result
call
attent
differ
phenotyp
bronchiol
earli
like
respond
differ
differ
therapi
natur
cours
asthma
incept
may
modifi
children
identifi
earli
even
time
first
wheez
episod
target
effect
intervent
strategi
